KR880007088A - 조직단백질 pp4를 함유하는 약제, pp4의 제조방법, 이의 저온살균법 및 용도 - Google Patents

조직단백질 pp4를 함유하는 약제, pp4의 제조방법, 이의 저온살균법 및 용도 Download PDF

Info

Publication number
KR880007088A
KR880007088A KR870014371A KR870014371A KR880007088A KR 880007088 A KR880007088 A KR 880007088A KR 870014371 A KR870014371 A KR 870014371A KR 870014371 A KR870014371 A KR 870014371A KR 880007088 A KR880007088 A KR 880007088A
Authority
KR
South Korea
Prior art keywords
optionally
adsorbent
solution
pasteurization
tissue protein
Prior art date
Application number
KR870014371A
Other languages
English (en)
Other versions
KR960007922B1 (ko
Inventor
뢰베르만 하르트무트
보른만 크리스티앙
Original Assignee
필립 스타인, 헤리베르트 부크
베링베르케 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 필립 스타인, 헤리베르트 부크, 베링베르케 아크티엔게젤샤프트 filed Critical 필립 스타인, 헤리베르트 부크
Publication of KR880007088A publication Critical patent/KR880007088A/ko
Application granted granted Critical
Publication of KR960007922B1 publication Critical patent/KR960007922B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0023—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/04—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Dental Preparations (AREA)

Abstract

내용 없음.

Description

조직단백질 PP4를 함유하는 약제, PP4의 제조방법, 이의 저온살균법 및 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 유효량의 PP4 및 약제학적으로 적합한 비히클 및/또는 안정화제를 함유하는, 응혈증의 치료 또는 예방용 약제.
  2. 제1항에 있어서, 혈액에 대해 등장성이며 경우에 따라 살균제를 함유하는 수용액 형태의 약제.
  3. 제1항에 있어서, 경우에 따라 첨가제 및 안정화제를 함유하는 동결건조물 형태의 약제.
  4. 제1항에 있어서, ml당 0.001 내지 100mp의 PP4를 함유하는 액체 형태의 약제.
  5. 제1항에 있어서, 동결건조된 형태의 약제.
  6. PP4를 함유하는 용액, 바람직하게는 PP4를 함유하는 조직추출물을 수불용성인 소수성 흡착제와 접촉시키고, 상등액으로부터 흡착제를 제거한 다음, 경우에 따라 완충제로 세척하고 PP4를 용출시킴을 특징으로 하여, PP4를 정제하는 방법.
  7. 제6항에 있어서, 흡착제가 지방족 또는 방향족 그룹을 함유하는 담체물질인 방법.
  8. PP4를 함유하는 용액을, 병원성 유기체를 사멸시킬 수 있는 조건하에서, 칼슘이온 및 적어도 하나의 단당류, 올리고당류 또는 당알코올, 및 경우에 따라 아미노산의 존재하에 가열시킴을 특징으로 하여, PP를 함유하는 용액을 저온살균시키는 방법.
  9. 혈액응괴를 억제시키기 위한 조직 단백질 PP4의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870014371A 1986-12-18 1987-12-17 조직단백질 pp4의 저온살균법 KR960007922B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP3643182.6 1986-12-18
DE19863643182 DE3643182A1 (de) 1986-12-18 1986-12-18 Arzneimittel enthaltend das gewebeprotein pp4, verfahren zur herstellung von pp4 und zu seiner pasteurisierung sowie die verwendung von pp4

Publications (2)

Publication Number Publication Date
KR880007088A true KR880007088A (ko) 1988-08-26
KR960007922B1 KR960007922B1 (ko) 1996-06-17

Family

ID=6316431

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870014371A KR960007922B1 (ko) 1986-12-18 1987-12-17 조직단백질 pp4의 저온살균법

Country Status (13)

Country Link
US (1) US5097019A (ko)
EP (3) EP0457370B1 (ko)
JP (1) JP2532535B2 (ko)
KR (1) KR960007922B1 (ko)
AT (2) ATE75618T1 (ko)
AU (1) AU622102B2 (ko)
CA (1) CA1338395C (ko)
DE (3) DE3643182A1 (ko)
DK (3) DK167900B1 (ko)
ES (2) ES2042532T3 (ko)
FI (1) FI91218C (ko)
GR (1) GR3005247T3 (ko)
PT (1) PT86393B (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE416151B (sv) * 1978-10-03 1980-12-01 Ake Gunnar Bolmgren Byggelement jemte mursten for tillverkning av elementet
DE3737239A1 (de) * 1987-11-03 1989-10-12 Behringwerke Ag Gentechnische herstellung von anticoagulatorischem protein pp4
NZ232813A (en) * 1989-03-10 1992-08-26 Snow Brand Milk Products Co Ltd Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
DE3939346A1 (de) * 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
DE4003773A1 (de) * 1990-02-08 1991-08-14 Behringwerke Ag Verfahren zur reinigung von lipocortinen
US5968477A (en) 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
US20030220233A1 (en) 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins
JP2747979B2 (ja) * 1994-08-19 1998-05-06 雪印乳業株式会社 ヒト由来の糖蛋白質からなる生理活性因子を有効成分とする医薬
DE19734648A1 (de) 1997-08-11 1999-02-18 Dade Behring Marburg Gmbh Verwendung von Annexinen als Lupus Antikoagulans Kontrolle oder Standard in Gerinnungstesten
US7635680B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US7635676B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US20090291086A1 (en) * 2001-02-21 2009-11-26 Alavita Pharmaceuticals, Inc. Compositions and Methods for Treating Cerebral Thrombosis and Global Cerebral Ischemia
US7645739B2 (en) * 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
EP1379266B1 (en) * 2001-02-21 2007-04-18 SurroMed, Inc. Modified annexin proteins and prevention and treatment of thrombosis
US6982154B2 (en) * 2002-02-21 2006-01-03 Surromed, Inc. Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease
GB2542391A (en) 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4461833A (en) * 1982-06-23 1984-07-24 University Patents, Inc. Chromatographically purifying proteolytic procoagulant enzyme from animal tissue extract
DE3237512A1 (de) * 1982-10-09 1984-04-12 Behringwerke Ag, 3550 Marburg Verfahren zur pasteurisierung von antihaemophilem kryopraezipitat (ahk) und danach hergestelltes antihaemophiles kryopraezipitat
DE3315000A1 (de) * 1983-04-26 1984-10-31 Behringwerke Ag, 3550 Marburg Gewebeprotein pp(pfeil abwaerts)4(pfeil abwaerts), verfahren zu seiner gewinnung sowie seine verwendung
CA1265446A (en) * 1985-09-30 1990-02-06 Masahiro Maki Anticoagulating substance, process for preparing same and anticoagulant comprising same as an effective component
DE3724726A1 (de) * 1987-07-25 1989-02-02 Behringwerke Ag Verfahren zur reinigung des plazentaren gewebeproteins pp4
US4896172A (en) * 1987-11-20 1990-01-23 Canon Kabushiki Kaisha Liquid injection recording apparatus including recording liquid circulation control

Also Published As

Publication number Publication date
FI91218C (fi) 1994-06-10
DK665787A (da) 1988-06-19
EP0271885A3 (en) 1988-09-21
DK665787D0 (da) 1987-12-17
ATE75618T1 (de) 1992-05-15
DE3643182A1 (de) 1988-06-30
FI875518A (fi) 1988-06-19
DK36093D0 (da) 1993-03-26
DE3751281D1 (de) 1995-06-08
ATE121940T1 (de) 1995-05-15
FI91218B (fi) 1994-02-28
AU8264687A (en) 1988-06-23
JP2532535B2 (ja) 1996-09-11
KR960007922B1 (ko) 1996-06-17
DE3778852D1 (de) 1992-06-11
PT86393B (pt) 1990-11-20
GR3005247T3 (ko) 1993-05-24
EP0457371A1 (de) 1991-11-21
FI875518A0 (fi) 1987-12-16
DK36093A (da) 1993-03-26
DK35993D0 (da) 1993-03-26
JPS63165328A (ja) 1988-07-08
PT86393A (en) 1988-01-01
DK35993A (da) 1993-03-26
EP0271885B1 (de) 1992-05-06
EP0271885A2 (de) 1988-06-22
EP0457370B1 (de) 1995-05-03
US5097019A (en) 1992-03-17
DK167900B1 (da) 1994-01-03
ES2072490T3 (es) 1995-07-16
ES2042532T3 (es) 1993-12-16
AU622102B2 (en) 1992-04-02
EP0457370A1 (de) 1991-11-21
CA1338395C (en) 1996-06-11

Similar Documents

Publication Publication Date Title
KR880007088A (ko) 조직단백질 pp4를 함유하는 약제, pp4의 제조방법, 이의 저온살균법 및 용도
ES2187798T3 (es) Procedimiento de conservacion de virus recombinantes infecciosos, suspension acuosa viral y su utilizacion como medicamento.
KR910002467A (ko) lgM을 함유하는 정맥내 투여용 폴리클로날 면역글로블린 제제 및 이의 제조방법
DE3400413A1 (de) Pasteurisierte, therapeutisch aktive faktor-ix-konzentrate und verfahren zu deren herstellung
EP0106608B1 (en) Method of lyophilizing cold insoluble globulin
HU210026B (en) Heparin-free composition for stabilizing blood plasma during pasteurization, and process for pasteurizing blood plasma
US3227626A (en) Plasminogen heat sterilization
KR950010321B1 (ko) 인간 트롬빈 제제의 가열처리방법
Docherty et al. Inactivation of herpes simplex virus types 1 and 2 by synthetic histidine peptides
KR940013339A (ko) 활성 유(乳) 단백질 성분 함유 제품 및 그 제조방법
ES2080155T3 (es) Procedimiento de pasteurizacion y cola pasteurizada para unir tejidos humano o animal.
SU1138167A1 (ru) Способ лечени асептических послеоперационных ран
JPS6140392B2 (ko)
RU2169553C1 (ru) Гель для лечения ран
Caspi et al. Does serum degrade amyloid fibrils? Failure to confirm enzymatic degradation of amyloid A fibrils as the basis of the so-called “amyloid degrading activity” of serum
KR960000232A (ko) 소디업 카복시메틸셀루로즈(sodium carboxymethylcellulose)와 덱스트란 70(dextran 70)을 함유한 사람 및 동물의 복강장기 유착방지제

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee